|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Emerging Treatments and Technologies |
Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone
University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas
OBJECTIVE—To elucidate the effects of pioglitazone treatment on glucose and lipid metabolism in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS—A total of 23 diabetic patients (age 30–70 years, BMI < 36 kg/m2) who were being treated with a stable dose of sulfonylurea were randomly assigned to receive either placebo (n = 11) or pioglitazone (45 mg/day) (n = 12) for 16 weeks. Before and after 16 weeks of treatment, all subjects received a 75-g oral glucose tolerance test (OGTT); and hepatic and peripheral insulin sensitivity was measured with a two-step euglycemic insulin (40 and 160 mU · min-1 · m–2) clamp performed with 3-[3H]glucose and indirect calorimetry. HbA1c was measured monthly throughout the study period.
RESULTS—After 16 weeks of pioglitazone treatment, the fasting plasma glucose (FPG; 184 ± 15 to 135 ± 11 mg/dl, P < 0.01), mean plasma glucose during OGTT (293 ± 12 to 225 ± 14 mg/dl, P < 0.01), and HbA1c (8.9 ± 0.3 to 7.2 ± 0.5%, P < 0.01) decreased significantly without change in fasting or glucose-stimulated insulin/C-peptide concentrations. Fasting plasma free fatty acid (FFA; 647 ± 39 to 478 ± 49 µEq/l, P < 0.01) and mean plasma FFA during OGTT (485 ± 30 to 347 ± 33 µEq/l, P < 0.01) decreased significantly after pioglitazone treatment. Before and after pioglitazone treatment, basal endogenous glucose production (EGP) and FPG were strongly correlated (r = 0.67, P < 0.01). EGP during the first insulin clamp step was significantly decreased after pioglitazone treatment (P < 0.05), whereas insulin-stimulated total and nonoxidative glucose disposal during the second insulin clamp was increased (P < 0.01). The change in FPG was related to the change in basal EGP, EGP during the first insulin clamp step, and total glucose disposal during the second insulin clamp step. The change in mean plasma glucose concentration during the OGTT was strongly related to the change in total body glucose disposal during the second insulin clamp step.
CONCLUSIONS—These results suggest that pioglitazone therapy in type 2 diabetic patients decreases fasting and postprandial plasma glucose levels by improving hepatic and peripheral (muscle) tissue sensitivity to insulin.
Abbreviations: EGP, endogenous glucose production • FFA, free fatty acid • FFM, fat-free mass • FPG, fasting plasma glucose • FPI, fasting plasma insulin • OGTT, oral glucose tolerance test • PPAR, peroxisome proliferator–activated receptor
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Ravikumar, J. Gerrard, C. Dalla Man, M. J. Firbank, A. Lane, P. T. English, C. Cobelli, and R. Taylor Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content Diabetes, September 1, 2008; 57(9): 2288 - 2295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Approaches to Treatment of Type 2 Diabetes Diabetes Care, August 1, 2008; 31(8): 1697 - 1703. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Chess and W. C. Stanley Role of diet and fuel overabundance in the development and progression of heart failure Cardiovasc Res, July 15, 2008; 79(2): 269 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Riserus, D. Sprecher, T. Johnson, E. Olson, S. Hirschberg, A. Liu, Z. Fang, P. Hegde, D. Richards, L. Sarov-Blat, et al. Activation of Peroxisome Proliferator-Activated Receptor (PPAR){delta} Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men Diabetes, February 1, 2008; 57(2): 332 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fernandez, C. Triplitt, E. Wajcberg, A. A. Sriwijilkamol, N. Musi, K. Cusi, R. DeFronzo, and E. Cersosimo Addition of Pioglitazone and Ramipril to Intensive Insulin Therapy in Type 2 Diabetic Patients Improves Vascular Dysfunction by Different Mechanisms Diabetes Care, January 1, 2008; 31(1): 121 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Basu, P. Shah, A. Basu, B. Norby, B. Dicke, V. Chandramouli, O. Cohen, B. R. Landau, and R. A. Rizza Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes Diabetes, January 1, 2008; 57(1): 24 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D West, D. J Nicoll, T. M Wallace, D. R Matthews, and J. R Stradling Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes Thorax, November 1, 2007; 62(11): 969 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mittermayer, G. Schaller, J. Pleiner, K. Krzyzanowska, S. Kapiotis, M. Roden, and M. Wolzt Rosiglitazone Prevents Free Fatty Acid-Induced Vascular Endothelial Dysfunction J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2574 - 2580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Wajcberg, A. Sriwijitkamol, N. Musi, R. A. DeFronzo, and E. Cersosimo Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1256 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Stuart, M. E.A. Howell, and D. Yin Overexpression of GLUT5 in Diabetic Muscle Is Reversed by Pioglitazone Diabetes Care, April 1, 2007; 30(4): 925 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo Thiazolidinediones improve beta-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hanefeld, N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study J. Am. Coll. Cardiol., January 23, 2007; 49(3): 290 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gastaldelli, Y. Miyazaki, A. Mahankali, R. Berria, M. Pettiti, E. Buzzigoli, E. Ferrannini, and R. A. DeFronzo The Effect of Pioglitazone on the Liver: Role of adiponectin Diabetes Care, October 1, 2006; 29(10): 2275 - 2281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Imayama, T. Ichiki, K. Inanaga, H. Ohtsubo, K. Fukuyama, H. Ono, Y. Hashiguchi, and K. Sunagawa Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor {gamma} Cardiovasc Res, October 1, 2006; 72(1): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gastaldelli, Y. Miyazaki, M. Pettiti, E. Santini, D. Ciociaro, R. A. DeFronzo, and E. Ferrannini The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 806 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nishio, M. Sakurai, T. Kusuyama, M. Shigemitsu, T. Fukui, K. Kawamura, S. Itoh, N. Konno, and T. Katagiri A Randomized Comparison of Pioglitazone to Inhibit Restenosis After Coronary Stenting in Patients With Type 2 Diabetes Diabetes Care, January 1, 2006; 29(1): 101 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kendall Thiazolidinediones: The case for early use Diabetes Care, January 1, 2006; 29(1): 154 - 157. [Full Text] [PDF]
|
|
|
|
|
|
C.-Y. Lin, T. Gurlo, L. Haataja, W. A. Hsueh, and P. C. Butler Activation of Peroxisome Proliferator-Activated Receptor-{gamma} by Rosiglitazone Protects Human Islet Cells against Human Islet Amyloid Polypeptide Toxicity by a Phosphatidylinositol 3'-Kinase-Dependent Pathway J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6678 - 6686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Christensen, B. Meibohm, E. V. Capparelli, P. Velasquez-Mieyer, G. A. Burghen, and W. V. Tamborlane Single- and Multiple-Dose Pharmacokinetics of Pioglitazone in Adolescents With Type 2 Diabetes J. Clin. Pharmacol., October 1, 2005; 45(10): 1137 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Staels and J.-C. Fruchart Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists Diabetes, August 1, 2005; 54(8): 2460 - 2470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.R. Langenfeld, T. Forst, C. Hohberg, P. Kann, G. Lubben, T. Konrad, S.D. Fullert, C. Sachara, and A. Pfutzner Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes Mellitus: Results From a Controlled Randomized Study Circulation, May 17, 2005; 111(19): 2525 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. McMahon, J. Plutzky, E. Daher, T. Bhattacharyya, G. Grunberger, and M. F. DiCarli Effect of a Peroxisome Proliferator-Activated Receptor-{gamma} Agonist on Myocardial Blood Flow in Type 2 Diabetes Diabetes Care, May 1, 2005; 28(5): 1145 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Tan, A. Baksi, B. Krahulec, P. Kubalski, A. Stankiewicz, R. Urquhart, G. Edwards, D. Johns, and for the GLAL Study Group Comparison of Pioglitazone and Gliclazide in Sustaining Glycemic Control Over 2 Years in Patients With Type 2 Diabetes Diabetes Care, March 1, 2005; 28(3): 544 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Abdelrahman, A. Sivarajah, and C. Thiemermann Beneficial effects of PPAR-{gamma} ligands in ischemia-reperfusion injury, inflammation and shock Cardiovasc Res, March 1, 2005; 65(4): 772 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ceriello, D. Johns, M. Widel, D. J. Eckland, K. J. Gilmore, and M. H. Tan Comparison of Effect of Pioglitazone With Metformin or Sulfonylurea (Monotherapy and Combination Therapy) on Postload Glycemia and Composite Insulin Sensitivity Index During an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes Diabetes Care, February 1, 2005; 28(2): 266 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Kintscher and R. E. Law PPAR{gamma}-mediated insulin sensitization: the importance of fat versus muscle Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E287 - E291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Miyazaki, E. De Filippis, M. Bajaj, E. Wajcberg, L. Glass, C. Triplitt, E. Cersosimo, L. J Mandarino, and R. A Defronzo Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1): 28 - 35. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Chiquette, G. Ramirez, and R. DeFronzo A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors Arch Intern Med, October 25, 2004; 164(19): 2097 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Huss and D. P. Kelly Nuclear Receptor Signaling and Cardiac Energetics Circ. Res., September 17, 2004; 95(6): 568 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yki-Jarvinen Thiazolidinediones N. Engl. J. Med., September 9, 2004; 351(11): 1106 - 1118. [Full Text] [PDF]
|
|
|
|
|
|
Y. Miyazaki, A. Mahankali, E. Wajcberg, M. Bajaj, L. J. Mandarino, and R. A. DeFronzo Effect of Pioglitazone on Circulating Adipocytokine Levels and Insulin Sensitivity in Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4312 - 4319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Strowig, M. L. Aviles-Santa, and P. Raskin Improved Glycemic Control Without Weight Gain Using Triple Therapy in Type 2 Diabetes Diabetes Care, July 1, 2004; 27(7): 1577 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Charbonnel, J. Dormandy, E. Erdmann, M. Massi-Benedetti, and A. Skene The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients Diabetes Care, July 1, 2004; 27(7): 1647 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Keen, M. J. Ryan, A. Beyer, S. Mathur, T. E. Scheetz, B. D. Gackle, F. M. Faraci, T. L. Casavant, and C. D. Sigmund Gene expression profiling of potential PPAR{gamma} target genes in mouse aorta Physiol Genomics, June 17, 2004; 18(1): 33 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gotto Jr and E. A. Brinton Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update J. Am. Coll. Cardiol., March 3, 2004; 43(5): 717 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bays, L. Mandarino, and R. A. DeFronzo Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478. [Full Text] [PDF]
|
|
|
|
|
|
M. Hanefeld, P. Brunetti, G. H. Schernthaner, D. R. Matthews, and B. H. Charbonnel One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes Diabetes Care, January 1, 2004; 27(1): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Diani, G. Sawada, B. Wyse, F. T. Murray, and M. Khan Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E116 - E122. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. P.H. van Wijk, E. J.P. de Koning, E. P. Martens, and T. J. Rabelink Thiazolidinediones and Blood Lipids in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1744 - 1749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Winkler, T. Konrad, S. Fullert, I. Friedrich, R. Destani, M. W. Baumstark, K. Krebs, H. Wieland, and W. Marz Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension: A double-blind, placebo-controlled study Diabetes Care, September 1, 2003; 26(9): 2588 - 2594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Miyazaki, H. He, L. J. Mandarino, and R. A. DeFronzo Rosiglitazone Improves Downstream Insulin Receptor Signaling in Type 2 Diabetic Patients Diabetes, August 1, 2003; 52(8): 1943 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Wilmsen, T. P. Ciaraldi, L. Carter, N. Reehman, S. R. Mudaliar, and R. R. Henry Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E354 - E362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Varo, D. Vicent, P. Libby, R. Nuzzo, A. L. Calle-Pascual, M. R. Bernal, A. Fernandez-Cruz, A. Veves, P. Jarolim, J. J. Varo, et al. Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones Circulation, June 3, 2003; 107(21): 2664 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bajaj, S. Suraamornkul, T. Pratipanawatr, L. J. Hardies, W. Pratipanawatr, L. Glass, E. Cersosimo, Y. Miyazaki, and R. A. DeFronzo Pioglitazone Reduces Hepatic Fat Content and Augments Splanchnic Glucose Uptake in Patients With Type 2 Diabetes Diabetes, June 1, 2003; 52(6): 1364 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Pavo, G. Jermendy, T. T. Varkonyi, Z. Kerenyi, A. Gyimesi, S. Shoustov, M. Shestakova, M. Herz, D. Johns, B. J. Schluchter, et al. Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1637 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Miles, D. Wooldridge, W. J. Grellner, S. Windsor, W. L. Isley, S. Klein, and W. S. Harris Nocturnal and Postprandial Free Fatty Acid Kinetics in Normal and Type 2 Diabetic Subjects: Effects of Insulin Sensitization Therapy Diabetes, March 1, 2003; 52(3): 675 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laplante, H. Sell, K. L. MacNaul, D. Richard, J. P. Berger, and Y. Deshaies PPAR-{gamma} Activation Mediates Adipose Depot-Specific Effects on Gene Expression and Lipoprotein Lipase Activity: Mechanisms for Modulation of Postprandial Lipemia and Differential Adipose Accretion Diabetes, February 1, 2003; 52(2): 291 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A Defronzo Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance? The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1_suppl): S24 - S40. [Abstract] [PDF]
|
|
|
|
|
|
A. Gastaldelli, Y. Miyazaki, M. Pettiti, M. Matsuda, S. Mahankali, E. Santini, R. A. DeFronzo, and E. Ferrannini Metabolic Effects of Visceral Fat Accumulation in Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5098 - 5103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ljung, K. Bamberg, B. Dahllof, A. Kjellstedt, N. D. Oakes, J. Ostling, L. Svensson, and G. Camejo AZ 242, a novel PPAR{alpha}/{gamma} agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats J. Lipid Res., November 1, 2002; 43(11): 1855 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Strowig, M. L. Aviles-Santa, and P. Raskin Comparison of Insulin Monotherapy and Combination Therapy With Insulin and Metformin or Insulin and Troglitazone in Type 2 Diabetes Diabetes Care, October 1, 2002; 25(10): 1691 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Meyer, K. Levin, T. Grimmsmann, N. Perwitz, A. Eirich, H. Beck-Nielsen, and H. H. Klein Troglitazone Treatment Increases Protein Kinase B Phosphorylation in Skeletal Muscle of Normoglycemic Subjects at Risk for the Development of Type 2 Diabetes Diabetes, September 1, 2002; 51(9): 2691 - 2697. [Abstract] [Full Text] [PDF]
|
|